Ornithine decarboxylase as an enzyme target for therapy

Peter P. McCann; Anthony E. Pegg

doi:10.1016/0163-7258(92)90032-U

Ornithine decarboxylase as an enzyme target for therapy

Peter P. McCann, Anthony E. Pegg

Research output: Contribution to journal › Review article › peer-review

241 Scopus citations

Abstract

Interest in ornithine decarboxylase (ODC) and the therapeutic effects of its inhibition with the consequent depletion of polyamine biosynthesis has been widespread since the late 1970s and 1980s. This review covers new information about the properties of ODC, recent findings with ODC inhibitors and a discussion of the mechanism of inactivation of ODC by eflornithine. Recent in vivo therapeutic approaches of ODC inhibition are also discussed including: cancer and cancer chemoprevention; autoimmune diseases; polyamines and the blood-brain barrier, ischemia and hyperplasia; the NMDA receptor and modulation by polyamines; hearing loss; African trypanosomiasis; Pneumocystis carinii pneumonia and Cryptosporidium in AIDS; and other infectious diseases/organisms.

Original language	English (US)
Pages (from-to)	195-215
Number of pages	21
Journal	Pharmacology and Therapeutics
Volume	54
Issue number	2
DOIs	https://doi.org/10.1016/0163-7258(92)90032-U
State	Published - 1992

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0163-7258(92)90032-U

Cite this

@article{77f9dc1fc0de4d98b90aa2cbfd31e98a,

title = "Ornithine decarboxylase as an enzyme target for therapy",

abstract = "Interest in ornithine decarboxylase (ODC) and the therapeutic effects of its inhibition with the consequent depletion of polyamine biosynthesis has been widespread since the late 1970s and 1980s. This review covers new information about the properties of ODC, recent findings with ODC inhibitors and a discussion of the mechanism of inactivation of ODC by eflornithine. Recent in vivo therapeutic approaches of ODC inhibition are also discussed including: cancer and cancer chemoprevention; autoimmune diseases; polyamines and the blood-brain barrier, ischemia and hyperplasia; the NMDA receptor and modulation by polyamines; hearing loss; African trypanosomiasis; Pneumocystis carinii pneumonia and Cryptosporidium in AIDS; and other infectious diseases/organisms.",

author = "McCann, {Peter P.} and Pegg, {Anthony E.}",

year = "1992",

doi = "10.1016/0163-7258(92)90032-U",

language = "English (US)",

volume = "54",

pages = "195--215",

journal = "Pharmacology and Therapeutics",

issn = "0163-7258",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Ornithine decarboxylase as an enzyme target for therapy

AU - McCann, Peter P.

AU - Pegg, Anthony E.

PY - 1992

Y1 - 1992

N2 - Interest in ornithine decarboxylase (ODC) and the therapeutic effects of its inhibition with the consequent depletion of polyamine biosynthesis has been widespread since the late 1970s and 1980s. This review covers new information about the properties of ODC, recent findings with ODC inhibitors and a discussion of the mechanism of inactivation of ODC by eflornithine. Recent in vivo therapeutic approaches of ODC inhibition are also discussed including: cancer and cancer chemoprevention; autoimmune diseases; polyamines and the blood-brain barrier, ischemia and hyperplasia; the NMDA receptor and modulation by polyamines; hearing loss; African trypanosomiasis; Pneumocystis carinii pneumonia and Cryptosporidium in AIDS; and other infectious diseases/organisms.

AB - Interest in ornithine decarboxylase (ODC) and the therapeutic effects of its inhibition with the consequent depletion of polyamine biosynthesis has been widespread since the late 1970s and 1980s. This review covers new information about the properties of ODC, recent findings with ODC inhibitors and a discussion of the mechanism of inactivation of ODC by eflornithine. Recent in vivo therapeutic approaches of ODC inhibition are also discussed including: cancer and cancer chemoprevention; autoimmune diseases; polyamines and the blood-brain barrier, ischemia and hyperplasia; the NMDA receptor and modulation by polyamines; hearing loss; African trypanosomiasis; Pneumocystis carinii pneumonia and Cryptosporidium in AIDS; and other infectious diseases/organisms.

UR - http://www.scopus.com/inward/record.url?scp=0026671825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026671825&partnerID=8YFLogxK

U2 - 10.1016/0163-7258(92)90032-U

DO - 10.1016/0163-7258(92)90032-U

M3 - Review article

C2 - 1438532

AN - SCOPUS:0026671825

SN - 0163-7258

VL - 54

SP - 195

EP - 215

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

IS - 2

ER -

Ornithine decarboxylase as an enzyme target for therapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this